These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 16990957)

  • 41. Comparison of N-terminal pro-B-natriuretic peptide, C-reactive protein, and creatinine clearance for prognosis in patients with known coronary heart disease.
    Rothenbacher D; Koenig W; Brenner H
    Arch Intern Med; 2006 Dec 11-25; 166(22):2455-60. PubMed ID: 17159010
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High-sensitivity C-reactive protein level is a significant risk factor for silent cerebral infarction in patients on hemodialysis.
    Anan F; Shimomura T; Kaku T; Kaneda K; Imagawa M; Tsukagawa H; Masaki T; Nawata T; Yonemochi H; Eshima N; Saikawa T; Yoshimatsu H
    Metabolism; 2008 Jan; 57(1):66-70. PubMed ID: 18078860
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association between protein bound sialic acid and high sensitivity C-reactive protein in prehypertension: a possible indication of underlying cardiovascular risk.
    Sathiyapriya V; Selvaraj N; Nandeesha H; Bobby Z; Aparna A; Pavithran P
    Clin Exp Hypertens; 2008 Jul; 30(5):367-74. PubMed ID: 18633759
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inflammation, atherosclerosis, and stroke.
    Elkind MS
    Neurologist; 2006 May; 12(3):140-8. PubMed ID: 16688015
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relation of C-reactive protein to abdominal adiposity.
    Brooks GC; Blaha MJ; Blumenthal RS
    Am J Cardiol; 2010 Jul; 106(1):56-61. PubMed ID: 20609648
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Evaluation of clinical usefulness of selected laboratory markers in the prediction of myocardial infarction in patients under secondary prevention].
    Plak M; Łobos M; Religa W; Tokarek A; Bonar A; Janas B; Paradowski M
    Pol Merkur Lekarski; 2011 Jul; 31(181):9-14. PubMed ID: 21870702
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Improving overall men's health and potentially reducing the risk of certain cancers via serum markers and risk assessment for coronary heart disease.
    Moyad MA
    Urol Oncol; 2004; 22(6):485-9. PubMed ID: 15610866
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Introduction to risk assessment and serum risk markers for the prevention of coronary heart disease and other potential conditions that impact men's health, part II: what do I tell my patients?
    Moyad MA
    Urol Clin North Am; 2004 May; 31(2):199-205. PubMed ID: 15123399
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lipid screening to prevent coronary artery disease: a quantitative evaluation of evolving guidelines.
    Grover SA; Dorais M; Paradis G; Fodor JG; Frohlich JJ; McPherson R; Coupal L; Zowall H
    CMAJ; 2000 Nov; 163(10):1263-9. PubMed ID: 11107461
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biomarkers of outcome from cardiovascular disease.
    Khuseyinova N; Koenig W
    Curr Opin Crit Care; 2006 Oct; 12(5):412-9. PubMed ID: 16943718
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [High sensitivity C reactive protein and lipid status as a risk factors for coronary disease].
    Nurkić J; Nurkić M; Nurkić M
    Med Arh; 2007; 61(3):138-41. PubMed ID: 18232274
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum markers of vascular inflammation in dyslipemia.
    Francisco G; Hernández C; Simó R
    Clin Chim Acta; 2006 Jul; 369(1):1-16. PubMed ID: 16469304
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The role of C-reactive protein and other acute phase markers in atherosclerosis].
    Gusev DE; Ponomar' EG
    Klin Med (Mosk); 2006; 84(5):25-30. PubMed ID: 16827274
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the clinical practice discussion group.
    Smith SC; Anderson JL; Cannon RO; Fadl YY; Koenig W; Libby P; Lipshultz SE; Mensah GA; Ridker PM; Rosenson R; ;
    Circulation; 2004 Dec; 110(25):e550-3. PubMed ID: 15611380
    [No Abstract]   [Full Text] [Related]  

  • 55. U.S. Preventive Services Task Force: screening for lipid disorders in adults: recommendations and rationale.
    Berg AO; Atkins D;
    Am J Nurs; 2002 Jun; 102(6):91, 93, 95. PubMed ID: 12394084
    [No Abstract]   [Full Text] [Related]  

  • 56. Assessment of risk factors for coronary heart disease in vascular medicine: long-term experience and a personal view from the laboratory.
    Demacker PN
    Semin Vasc Med; 2004 Feb; 4(1):23-9. PubMed ID: 15199430
    [TBL] [Abstract][Full Text] [Related]  

  • 57. C-reactive protein, heart disease risk, and the popular media.
    Tracy RP; Kuller LH
    Arch Intern Med; 2005 Oct; 165(18):2058-60. PubMed ID: 16216994
    [No Abstract]   [Full Text] [Related]  

  • 58. The case for C-reactive protein as a risk marker for coronary heart disease.
    Cook NR
    Ann Intern Med; 2010 Mar; 152(6):406; author reply 406-7. PubMed ID: 20231582
    [No Abstract]   [Full Text] [Related]  

  • 59. The USPSTF recommendation statement on coronary heart disease risk assessment.
    Glynn RJ
    Ann Intern Med; 2010 Mar; 152(6):403; author reply 405-6. PubMed ID: 20231577
    [No Abstract]   [Full Text] [Related]  

  • 60. Clinical inquiries. What is the value of screening for heart disease with an exercise stress test (EST) in an asymptomatic person?
    Zamorski MA; Fields KB
    J Fam Pract; 2001 Oct; 50(10):844. PubMed ID: 11674885
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.